CSTEAM biotechnology is a forward-thinking company based in Ohio, USA, dedicated to the research and development of cutting-edge biotechnology products. Our focus spans four main areas: gene and cell therapies, biochips, gene-edited biological models, and antibodies. We have led the way in creating dual-target CAR-T cell therapies aimed at CD38 and BCMA for treating blood cancers, and we have also developed autologous young stem cell therapies to address chronic conditions like liver fibrosis and pulmonary fibrosis. Additionally, we are at the forefront of innovation with our spatial histology-based system for analyzing tumor heterogeneity and a multifunctional lab-on-a-chip designed to differentiate between benign and malignant pulmonary nodules. In the field of gene-edited biological models, we have created a variety of cellular, organoid, and mouse models that closely replicate human diseases. Our antibody development includes monoclonal, polyclonal, and recombinant antibodies. Our mission is to enhance cancer treatment through our innovative cell therapies, improve diagnostic precision with our biochip technology, and provide valuable disease models and antibodies for scientific research through our advancements in gene editing and antibody engineering. CSTEAM biotechnology is committed to fostering collaboration with universities, research institutions, hospitals, and pharmaceutical companies, actively working to accelerate the development of groundbreaking biotechnology products that can benefit people worldwide.